Trending NewsTrending NewsNASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis $105.22 +2.68 (+2.61%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$105.18 -0.04 (-0.04%) As of 07:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvalent Stock (NASDAQ:NUVL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvalent alerts:Sign Up Key Stats Today's Range$101.50▼$106.2150-Day Range$94.77▼$108.8552-Week Range$68.64▼$113.01Volume400,987 shsAverage Volume586,912 shsMarket Capitalization$8.27 billionP/E RatioN/ADividend YieldN/APrice Target$137.25Consensus RatingModerate Buy Company Overview Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets. Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations. These assets are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with early data demonstrating favorable safety profiles and preliminary signs of clinical activity in patients with RET-driven and KRAS-mutant solid tumors. In addition to these core programs, Nuvalent continues to leverage its structure-based approach to advance discovery efforts and expand its portfolio into other oncogenic targets. The company conducts its operations primarily in North America, supported by strategic collaborations and investigator-led studies in international research centers. Under the leadership of President and Chief Executive Officer Bill Haney, Nuvalent has assembled a management team with extensive experience in oncology drug development, regulatory affairs and commercial planning. The organization remains committed to translating cutting-edge science into precision medicines that address unmet needs in cancer therapy.AI Generated. May Contain Errors. Read More Nuvalent Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreNUVL MarketRank™: Nuvalent scored higher than 58% of companies evaluated by MarketBeat, and ranked 387th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 16 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNuvalent has a consensus price target of $137.25, representing about 30.4% upside from its current price of $105.22.Amount of Analyst CoverageNuvalent has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nuvalent's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nuvalent are expected to grow in the coming year, from ($5.87) to ($4.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 7.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.78% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 8.27.Change versus previous monthShort interest in Nuvalent has recently increased by 10.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.19 News SentimentNuvalent has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Nuvalent this week, compared to 5 articles on an average week. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,235,217.00 in company stock.Percentage Held by Insiders5.02% of the stock of Nuvalent is held by insiders.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvalent's insider trading history. Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NUVL Stock News HeadlinesNuvalent (NASDAQ:NUVL) CEO Sells $3,050,700.00 in StockMay 7, 2026 | insidertrades.comNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comWhat is “gold skimming”?Former $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way to target cash payouts from gold markets without buying a single ounce, mining stock, or ETF. With a reported 73% win rate across 19 trades and potential payouts of $2,975, $3,781, and $6,786 in a single day, Benedict has put together a free step-by-step walkthrough showing how it works whether gold climbs or pulls back.May 14 at 1:00 AM | Brownstone Research (Ad)Canaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL)May 6, 2026 | theglobeandmail.comNuvalent (NUVL) to Release Quarterly Earnings on ThursdayMay 6, 2026 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 6, 2026 | americanbankingnews.comDeborah Ann Miller Sells 5,500 Shares of Nuvalent (NASDAQ:NUVL) StockMay 3, 2026 | americanbankingnews.comNuvalent (NASDAQ:NUVL) Insider Henry Pelish Sells 3,093 SharesApril 14, 2026 | insidertrades.comSee More Headlines NUVL Stock Analysis - Frequently Asked Questions How have NUVL shares performed this year? Nuvalent's stock was trading at $100.59 at the beginning of 2026. Since then, NUVL shares have increased by 4.6% and is now trading at $105.22. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by $0.04. When did Nuvalent IPO? Nuvalent (NUVL) raised $180 million in an IPO on Wednesday, July 28th 2021. The company issued 10,612,500 shares at $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Top institutional investors of Nuvalent include Pictet Asset Management Holding SA (0.52%), Candriam S.C.A. (0.50%), First Trust Advisors LP (0.06%) and Walleye Capital LLC (0.05%). Insiders that own company stock include Andrew A F Hack, Matthew Shair, James Richard Porter, Alexandra Balcom, Henry E Pelish, Deborah Ann Miller, Christopher Durant Turner, Darlene Noci and Emily Conley. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvalent own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvalent investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/07/2026Today5/14/20267th Annual Oncology Innovation Summit: Insights for ASCO & EHA5/27/2026Jefferies Global Healthcare Conference 20266/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NUVL's financial health is in the Green zone, according to TradeSmith. NUVL has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NUVL CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees40Year Founded2017Price Target and Rating Average Price Target for Nuvalent$137.25 High Price Target$158.00 Low Price Target$105.00 Potential Upside/Downside+30.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($6.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$425.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.11% Return on Assets-35.43% Debt Debt-to-Equity RatioN/A Current Ratio16.14 Quick Ratio15.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.94 per share Price / Book7.04Miscellaneous Outstanding Shares78,620,000Free Float74,670,000Market Cap$8.27 billion OptionableOptionable Beta1.15 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NUVL) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
